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Adrenal disease, whether primary, caused by defects in the hypothalamic–pituitary–adrenal 
(HPA) axis, or secondary, caused by defects outside the HPA axis, usually results in adrenal 
insufficiency, which requires lifelong daily replacement of corticosteroids. However, this 
kind of therapy is far from ideal as physiological demand for steroids varies considerably 
throughout the day and increases during periods of stress. The development of alternative 
curative strategies is therefore needed. In this review, we describe the latest technologies 
aimed at either isolating or generating de novo cells that could be used for novel, regen-
erative medicine application in the adrenocortical field.
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The adrenal cortex is the primary site of steroid synthesis, producing glucocorticoids under the 
control of the hypothalamic–pituitary–adrenal (HPA) axis and mineralocorticoids under the control 
of the renin–angiotensin system. Glucocorticoids affect carbohydrate metabolism and mediate the 
mammalian stress response, while mineralocorticoids control blood volume and salt homeostasis. 
For this reason, the adrenal cortex is essential for life.
The adrenal cortex originates in a group of mesoderm-derived cells lying between the urogenital 
ridge and the dorsal aorta, forming the precursors of the adrenal glands and the gonads, the 
adrenogonadal primordium (AGP) (1). At around embryonic day (e)9.0 in the mouse, these cells 
begin to express the transcription factor steroidogenic factor 1 (SF1), which is essential for both 
adrenal and gonadal development (2). SF1 not only binds to response elements in the promoter 
regions of steroidogenic genes to positively regulate their transcription but can also be considered 
a true effector of cell fate as it starts a genetic program driving embryonic mesenchymal cells 
toward a steroidogenic phenotype/lineage (3, 4); its absolute requirement for steroidogenesis 
has been recently demonstrated in vivo (5). Other than SF1, at least four additional transcription 
factors have been shown to be key determinants of adrenal cortex development: Wilms tumor 
1 (WT1), a zinc finger protein, and CBP/p300-interacting transactivator 2 (CITED2), which 
are both expressed at early stages in the urogenital ridge and synergistically promote adrenal 
development through induction of SF1 transcription (6, 7); pre-B-cell leukemia transcription 
factor 1 (PBX1), a homeodomain protein, which has been proposed to facilitate the access of 
important developmental factors (such as SF1) to chromatin to induce differentiation (8, 9); 
dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1 (DAX1) 
(10), whose mutations are associated with a variety of developmentally relevant conditions in 
the adrenal and gonads (11), such as adrenal hypoplasia congenita. Moreover, multiple pathways 
have been implicated in the fine-tuned regulation of adrenal cortex development and function 
[reviewed in Ref. (12–15)]. The contribution of each of these signaling pathways has been studied 
by employing either in vitro systems or animal models, such as genetic lineage tracing (16, 17). 
Not surprisingly, the alteration of some of these pathways, such as the WNT pathway, results in 
adrenal cancer [reviewed in Ref. (18)].
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The adult gland is divided into at least three distinct zones 
arranged concentrically around the medulla; the zona glomeru-
losa (ZG, which synthesizes mineralocorticoids), which lies just 
underneath the capsule, the zona fasciculata (ZF, which synthesizes 
glucocorticoids), and then the zona reticularis (which synthesizes 
adrenal androgens in humans and primates). Zonation occurs 
around birth [for review, see Ref. (12)].
Primary adrenal insufficiency is due to a number of adrenal 
disorders, and management of these patients can be challenging 
(19). Current treatments entail lifelong replacement with exog-
enous steroids. None suitably mimic the diurnal pattern of cortisol 
noted in healthy individuals, and objective variables to measure 
quality of replacement are lacking. Fine-tuning of replacement 
leaves only a narrow margin for improvement. Under-replacement 
can result in severe impairment of well-being and incipient crisis. 
Conversely, chronic over-replacement can lead to substantial 
morbidity including obesity, osteoporosis, and impaired glucose 
tolerance. Furthermore, despite attention to detail with regards 
to replacement regimens, overall standardized mortality ratio for 
patients with adrenal failure is ~2.1.
Transplantation of Adrenal Glands and 
Cells
Adrenal autotransplantation in humans is poorly characterized. 
A few surgeons tested the potential benefits of adrenal autotrans-
plantation in patients with Cushing’s disease since the early 1960s. 
At that time, replacement therapy with synthetic steroids was 
becoming the gold standard for patients with Cushing’s disease 
but they hypothesized that autotransplantation would be an effec-
tive alternative to lifelong therapy (20–26). Adrenals were mainly 
transplanted in the thigh, because it is an easily accessible site 
should the transplant become not viable and need removal. The 
degree of autotransplant survival was, however, questionable, at 
least in those cases where follow-up is available (27). More recently, 
a successful mother-to-daughter allograft has been reported in a 
pediatric patient who developed adrenal insufficiency following 
fulminant meningococcemia (28). Allotransplantations of whole 
adrenal–kidney or adrenal–kidney–pancreas have also been 
described in clinical reports (29, 30); however, these multiple 
organ transplants are only feasible and/or recommended when 
the recipients have severe co-morbidities.
The refinement of allotransplantation and xenotransplantation 
has been the focus of more recent research, where a variety of 
animal models have been employed. Hornsby and colleagues 
performed initial work, demonstrating that transplantation 
of human adrenocortical cells into adrenalectomized severe 
combined immunodeficiency (scid) mice could be an effective 
technique for the treatment of adrenal insufficiency (31). They also 
developed a model, in which they showed that co-transplantation 
in a polycarbonate cylinder of clonal or primary bovine adreno-
cortical cells with 3T3 fibroblasts into scid mice could rescue them 
from developing adrenal insufficiency (32, 33). 3T3 cells were 
either treated with mitomycin C or lethally irradiated (to prevent 
proliferation upon implantation) and were overexpressing FGF1 
(to aid vascularization).
Through their work, they also showed that transplanted 
adrenocortical cells (of either human or bovine origin) could 
survive and form a functional, vascularized tissue that was able to 
replace the host animal’s organ. The newly formed tissue was able 
to produce and secrete the necessary amounts of cortisol, albeit 
aldosterone was only produced by primary bovine adrenocortical 
cells, but not from clonal cells (32). One possible reason for this 
might be that bovine adrenocortical cells preparations, albeit 
derived from the ZF, could contain some ZG cells or that some 
ZF cells could transdifferentiate to a ZG phenotype. It was later 
shown, however, that ZF cells are incapable of giving rise to ZG 
cells (34). In the same study, Teebken and Scheumann showed 
that transplanting ZG cells can give rise to both ZG and ZF, thus 
making ZG cells more suitable for transplantation (34). This is 
presumable because the harvest of ZG cells might result in the 
inclusion of progenitor cells with bi-potency, given their loca-
tion in the subcapsular region close to fully mature ZG cells in 
mouse (16, 35) and rat (36, 37). More recently, using mouse cell 
fate mapping and gene-deletion tools, Freedman and colleagues 
demonstrated that ZF cells indeed derive from fully differentiated 
ZG cells through lineage conversion (38). Similar results were 
observed during adrenal autotransplantation in the spleen of 
adrenalectomized rats (39).
Furthermore, genetic modifications such as immortalization of 
bovine primary adrenocortical cultures with telomerase reverse 
transcriptase (hTERT) have been shown to be very effective in 
xenotransplantation procedures. This technique aids the expansion 
of adrenocortical cells in vitro leading to improved efficacy (40, 41). 
Although hTERT is known to be a key-tumorigenic factor, when 
expressed on its own it did not alter the properties of the donor’s 
adrenocortical cell (42).
Possible Platforms for Cell Transplantation
Other groups looked into harnessing the properties of the adrenal 
cortex extracellular matrix (ECM). It is well established that the 
ECM plays a significant role in organ growth and development, as 
well as function, by providing structural support and by regulating 
cell signaling and cell-to-cell interactions (43). The ECM of the 
adrenal cortex is quite complex, mainly composed of collagen IV, 
fibronectin, and laminin and it was postulated that different ECM 
components might affect the biological activity of cortical cells 
(44). In fact, primary cultures of human fetal adrenal cells seeded 
on collagen IV or laminin were found to be more proliferative, as 
opposed to fibronectin, which enhanced cell apoptosis. In addition, 
collagen increased cell sensitivity to ACTH, whereas fibronectin 
and laminin had the opposite effect (45).
Further work to assess the function of implanted cells seeded 
on a collagen matrix, using a mouse model with adrenal insuf-
ficiency, determined that treatment involving staged bilateral 
adrenalectomy of the animals and implantation of collagen 
sponges each time was the most beneficial. This protocol lead to 
a 100% survival rate (up from 42% in mice with only one implant 
and 0% in animal receiving the graft without cells) and reversal of 
adrenal insufficiency, supported by restoration of corticosterone 
levels and the expression of adrenal markers by the transplanted 
cells (46).
TABLe 1 | Details of published studies on adrenocortical or adrenogonwadal reprograming.
PMiD Article Cells Origin Methodology
9199334 Crawford PA, et al. Mol Cell Biol (1997) Embryonic stem cells (ESC) Mouse (RW4 129/SvJ) Stable transfection of SF1
15569155 Gondo S, et al. Genes Cells (2004) Bone marrow stem cells (BMCs) Mouse [C57BL/6Tg14  
(act-EGFP)osbY01]
Adenovirus SF1
16728492 Yazawa T, et al. Endocrinology (2006) Bone marrow stem cells (BMCs) Human (hMSChTERT-E6/E7) Stable transfection of SF1
17975261 Tanaka T, et al. J Mol Endocrinol (2007) Bone marrow stem cells (BMCs) Human (commercial cell line) Adenovirus SF1
18566117 Gondo S, et al. Endocrinology (2008) Adipose mesenchymal cells (AMCs) Mouse (C57BL/6J) (B6) Adenovirus SF1
19359379 Yazawa T, et al. Endocrinology (2009) Bone marrow stem cells (BMCs) Human (hMSChTERT-E6/E7) Retrovirus SF1/LRH-1
20133449 Yazawa T, et al. Mol Endocrinol (2010) Umbilical cord blood (UCB-MSCs) Human (umbilical cord blood) Retrovirus SF1
21129436 Yazawa T, et al. Mol Cell Endocrinol (2011) Embryonic stem cells (ESC) Mouse (EBRTcH3) Retrovirus (inducible SF1)
21610156 Jadhav U, et al. Endocrinology (2011) Embryonic stem cells (ESC) Mouse (R1 ES cell line) Stable transfection of SF1
21764617 Mazilu JK, et al. Mol Genet Metab (2011) Mesoderm-derived cells Human Adenoviral SF1/Dax1/Cited2/
Pbx1/WT1
22324479 Wei X, et al. Cell Prolif (2012) Umbilical cord mesenchymal stem 
cells (UC-MSCs)
Human (umbilical cord) Adenovirus SF1
22778223 Sonoyama T, et al. Endocrinology (2012) Embryonic Stem cell (ESC) iPS  
(from fibroblasts)
Human (H9 and KhES1)  
human (201B7)
Mesoderm diff. and 
nucleofection SF1
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Some researchers focused on the use of the native organ’s own 
decellularized ECM to act as a scaffold in transplantation procedures 
to regenerate various organs, including the heart, liver, and lungs 
(47). In vitro studies, using porcine decellularized adrenal ECM 
as a scaffold for human fetal adrenal cells, resulted in successful 
cell attachment and a good cell function, the latter assessed by cell 
proliferation and cortisol secretion (48). Therefore, decellularized 
adrenal ECM could represent an improved scaffold for transplanted 
cells, providing a native three-dimensional structure that would 
support growth and incorporation of transplanted cells into the 
native environment to form a fully functional adrenal tissue.
Stem Cells and Reprograming Strategies
An ever-increasing number of translational scientists are striving 
to take advantage of the remarkable properties of stem cells that 
are not only offering an unparalleled opportunity to study human 
biology and disease processes in vitro but also to translate basic 
scientific discoveries to therapeutic applications. The development 
of cell therapy has, however, been overlooked to date in field of 
endocrinology, with the exception of the worldwide effort to gener-
ate functional pancreatic beta cells to cure type-I diabetes. Indeed, 
the Californian company Viacyte has been granted FDA approval 
to launch the first clinical evaluation of a stem-cell-derived islet 
replacement therapy for the treatment of patients with type-I 
diabetes in 2015 (http://viacyte.com/clinical/clinical-trials/). 
Other clinical trials are in the pipeline, a culmination of decades 
of intense in vitro and animal studies carried out by dozens of 
laboratories (49). Despite the fact that the morbidity of diabetes 
vs. adrenal insufficiency is clearly not comparable, conceivably 
the search for alternative treatments for adrenal insufficiency has 
been neglected, except for a few important discoveries (see below).
Cellular reprograming describes the process where a fully 
differentiated, specialized cell type is induced to transform into 
a different cell type that it would not otherwise become under 
normal physiological conditions. Sir John Gurdon of Britain 
and Shinya Yamanaka of Japan were awarded the Nobel Prize in 
2012 for their groundbreaking discoveries in the field. Gurdon’s 
research showed that it was possible to reverse the specialization 
of cells. By transferring a nucleus from a frog’s intestinal cell into a 
frog’s egg cell that had its nucleus removed, he was able to obtain 
a tadpole. Building on Gurdon’s work, Yamanaka published a 
paper in 2006 demonstrating that mature murine cells can 
become immature stem cells (called inducible pluripotent stem 
cells, IPSCs) by expressing genes encoding four transcription 
factors (50). IPSCs can then be differentiated to several tissues 
using specific cocktails of growth factors/cytokines/chemical 
compounds. Yamanaka’s breakthrough opened the door to 
studying tissue-specific diseases and developing diagnosis and 
treatments. Reprograming is not only achieved through the 
generation of IPSCs but also through direct reprograming (also 
known as lineage conversion). Lineage conversion, which is usu-
ally achieved by forced expression of lineage-determining factors, 
is a recently developed and attractive alternative to obtain cells 
of a given lineage [reviewed in Ref. (51, 52)]. Lineage conversion 
into several clinically relevant cell types might also prove to be a 
safer alternative to IPSCs; in fact, genetic (copy number variation, 
chromosome duplication) and epigenetic variations, which have 
been described in IPSCs lines and that have raised a number of 
questions regarding the functional relevance as well as patient 
safety in potential translational applications, are uncommon 
during lineage conversion (51).
In recent years, several studies have shown the possibility of 
obtaining cells with steroidogenic properties resembling adreno-
cortical cells from murine and human cell sources (Table  1). 
Pioneering studies in mouse embryonic stem cells (ESCs) showed 
that the ectopically stable expression of SF1 in the presence of 
cAMP resulted in a dramatic change of cell morphology and 
subsequent upregulation of Cyp11a1 together with an induction of 
steroidogenesis. However, these cells were incapable of producing 
different steroid hormones de novo, since only progesterone was 
detected after treatment with 20α-hydroxycholesterol, a freely 
diffusible form of cholesterol (53).
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In 2004, Gondo and colleagues described the capacity of 
 long-term cultured mouse bone marrow cells (BMCs) to differenti-
ate into a steroidogenic lineage using adenoviral-mediated SF1 
overexpression (54). In this study, the authors were able to detect 
several steroidogenic enzymes and quantify the levels of all steroid 
hormones except aldosterone; further study showed that the cells 
failed to express Cyp11b2. Interestingly, reprogramed cells were 
responsive to ACTH, resulting in enhanced steroidogenic enzyme 
upregulation and hormone production. Despite the improvement 
in the steroidogenic profiling compared with the previous study, 
these cells showed a mixed pattern of adrenal and gonadal pheno-
types. Moreover, only supraphysiological concentrations of ACTH 
were able to significantly induce progesterone and deoxycortisone 
secretion. It also raises the question of the function of MC2R in 
BMCs physiology, as the authors found the receptor to be expressed 
in non-reprogramed cells.
The same group later obtained steroidogenic cells from mouse 
adipose tissue-derived mesenchymal cells (AMCs), using a similar 
strategy (55). Remarkably, when the steroidogenic gene expres-
sion profile and hormone production of AMCs and BMCs were 
compared, AMCs showed an enhanced cortisol/testosterone ratio 
compared with BMCs. This enrichment of the adrenocortical vs. 
gonadal phenotype was further potentiated by treatment with all-
trans retinoic acid (ATRA), suggesting that the tissue/cell source 
and the culture conditions are essential to determine the resultant 
phenotype during reprograming.
The first studies describing the generation of steroidogenic cells 
from human origin were from Miyamoto’s research group. In this 
work, human mesenchymal stem cells (hMSCs) stably expressing 
SF1 (as well as hTERT, E6, and E7) were able to upregulate steroido-
genic enzymes and produce both adrenal and gonadal steroids after 
treatment with cAMP. Immunohistochemical analysis of rat GFP+ 
BMCs injected into rat testes showed upregulation of steroidogenic 
enzymes in the engrafted cells (56). Taken together, these studies 
demonstrated that MSCs have the ability to differentiate into 
steroidogenic cells both in vivo and in vitro.
Since then, several groups have succeeded in differentiating 
human cells to a steroidogenic phenotype. Tanaka et al. efficiently 
reprogramed human BMCs upon overexpression of SF1 with 
adenovirus (57) and more recently this was achieved by retroviral 
overexpression of LRH-1 [like SF1, a member of the NR5A nuclear 
receptor family (58)]. However, it is likely that LRH-1 has a more 
prominent role in gonadal steroidogenesis in vivo, since LRH-1 is 
barely detectable in the adrenal cortex but highly expressed in the 
gonads, while SF1 is abundantly expressed in both adrenals and 
gonads (59, 60), and actually at higher levels in cells of the AGP 
destined to form the adrenal cortex (7).
Human steroidogenic-like cells were also successfully repro-
gramed from umbilical cord blood mesenchymal stem cells 
(UCB-MSCs) (61) and umbilical cord Wharton’s jelly-derived 
MSC (UC-MSCs) (62) through retroviral or adenoviral overexpres-
sion of SF1. In the latter study, the authors compared UC-MSCs 
with BM-MSCs and concluded that UCS-MSCs are the better 
cell sources since, after reprograming, these cells had a higher 
proliferative potential, expressed higher levels of steroidogenic 
enzymes, secreted more steroid hormones, and had a significantly 
higher cell viability.
Recently, several groups have changed their focus onto ESCs, 
as the first attempts to reprogram these cells were only partially 
successful (53). Yazawa et al. reported that to efficiently reprogram 
mouse ESCs (mESCs) to a steroidogenic phenotype, an initial 
differentiation to a mesenchymal lineage is needed (63). Once 
differentiation was achieved (using pulse exposures to ATRA and 
plating cells into collagen IV-coated dishes), cells became steroi-
dogenic upon overexpression of SF1, resulting in an upregulation 
of steroidogenic enzymes as well as steroid hormone production. 
Interestingly, the gene expression profile of these cells was similar 
to that of the zona fasciculata. Alternatively, Jadhav and Jameson 
provided evidence that steroidogenic cells can be produced from 
mESCs using different protocols, the most efficient involving the 
withdrawal of leukemia inhibitory factor from the ESC medium 
followed by treatment with cAMP. Using this protocol, steroid-
producing reprogramed ESCs appear to acquire a gonadal-like cell 
type lineage (64). Again, these works highlight the importance of 
the reprograming strategy/protocol to obtain a specific adrenal/
gonadal-like cell type.
Sonoyama et al. demonstrated the capacity of human ES cells 
(hESCs) to become steroidogenic (65). Using a similar approach 
as previously reported (63, 64), after differentiation of hESCs to 
a mesodermal lineage (in this case using a GSK3β inhibitor) and 
upon overexpression of SF1 and cAMP treatment, hESCs showed 
overexpression of steroidogenic enzymes as well as hormone 
production. The authors also obtained the first steroidogenic cells 
reprogramed from an IPSC line (201B7, obtained from human 
fibroblasts).
Despite none of the strategies described above have been tested 
in in vivo models of adrenal insufficiency (i.e., adrenalectomized 
animals), they provide strong evidence that cells can be repro-
gramed to a steroidogenic phenotype through overexpression 
of SF1 and cAMP treatment. The choice of the most appropriate 
source of cells as substrates for reprograming is still debated and 
might differ depending on downstream applications. Differences 
in species, cell/tissue source, cellular development stage, epigenetic 
landscape, SF1/transcription factors dosage (66), regulatory feed-
backs of activators/repressors, culture conditions, and timings of 
reprograming might affect the final phenotype of the reprogramed 
cells. In this regard, one cannot rule out the possibility that in 
order to generate fully functional adrenocortical cells, other tran-
scriptions factors might be needed. Factors, such as Dax1, Pbx1, 
Cited2, WT1, or WNT4, known to be associated with adrenal and 
gonadal development have been used in reprograming strategies 
with minor effects on steroidogenic outcome (57, 58, 67). However, 
given the importance of dosage and regulatory feedback between 
these key transcription factors, reprograming strategies using a 
combination of them at specific dosages might be indispensible 
to obtain cells with a steroidogenic pattern resembling the one 
found in vivo.
There are still several hurdles to overcome to efficiently 
reprogram human cells to be used for personalized cell-based 
therapies in patients with adrenal insufficiency in clinics: (1) the 
conditions to obtain cells with restricted adrenocortical-specific 
gene expression and hormone production are far from optimized 
(see above). (2) In most of the protocols, upon overexpression 
of SF1, cells terminally differentiate with a consequent growth 
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arrest. This makes it difficult to prepare the large amount of 
cells needed for cell therapy. The use of inducible vectors should 
allow the expression of SF1 (and/or other factors) at a desired 
culture time-point when there are enough cells for clinical 
purposes. (3) The methodologies used until now are all based 
on the overexpression of SF1 exogenously, either episomally 
or virally. Optimization of the culture conditions in a gene 
delivery-free model of reprograming might help to avoid the 
FiGURe 1 | This figure outlines novel and tested strategies for the 
treatment of adrenal insufficiency. Human embryonic stem (ES) cells (A) as 
well as somatic cells (such as fibroblasts, hair follicle dermal papillae, adipose 
tissue-derived stem cells, and urine-derived stem cells) established from 
human donors (B) can be cultured in vitro and induced to acquire an 
adrenocortical phenotype (C) through specific differentiation protocols. A 
gene-editing step can be included in case of monogenic disorders. 
Reprogramed cells that have successfully acquired an adrenocortical 
phenotype could then be implanted back into a donor, either inside an 
encapsulation device (D) or inside a decellularized adrenal of human or 
large-animal origin (G). While autotransplantation (H) has been trailed in 
humans in pioneering surgery during the 1960s (see text) and 
allotransplantation (e) has been a poorly tested option, xenotransplantation  
(F) has never been tested in humans.
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Recent Breakthroughs in Overcoming 
Rejection and the Treatment of Monogenic 
Diseases
A major factor limiting the application of stem-cell therapy in 
patients transplanted with ECs-derived adrenocortical cells or even 
autologous IPSCs-derived adrenocortical cells (i.e., in those indi-
viduals affected by autoimmune Addison’s) is the recipient’s need 
to adhere to lifelong immunosuppression. An effort going back a 
couple of decades in the field of biomaterials is providing us with 
the technology, which can make an impact in the clinical setting 
today; in fact, several encapsulation devices (endowed with excel-
lent biocompatibility) have been developed and are undergoing 
clinical testing in patients with type-I diabetes. Animal studies (49) 
and published preliminary human studies (69) have demonstrated 
that the device’s semipermeable membranes can tightly immune 
isolate transplanted cells while allowing diffusion of nutrients, 
such as glucose. Therefore, encapsulating adrenocortical cells 
is a strategy that should prevent rejection of the grafted tissue, 
whichever the source of it.
In recent times, a fast-paced development of gene-editing tech-
nologies using different approaches has made it possible to correct 
known disease-causing mutations without leaving any footprint 
(70). This technology could be successfully applicable to monogenic 
conditions causing adrenal insufficiency (such as congenital adrenal 
hyperplasia or familial glucocorticoid deficiency). For example, 
cultures of reprogrammable cell sources such as skin fibroblasts 
or urine-derived cells could be established and the mutated gene 
reverted to a wild-type status via gene editing; after successful 
reprograming to an adrenocortical phenotype (via IPSCs genera-
tion or via lineage conversion), cells could be reimplanted back 
into the donor, housed either inside an encapsulation device or a 
decellularized adrenal gland obtained from cadaver or large animal.
Potential future strategies, as well as pioneering past and 
present attempts to cure adrenal insufficiency are outlined in 
Figure 1.
In conclusion, while autotransplantation has long been 
discarded, allotransplantation is currently being considered 
only in specific clinical settings and xenotransplantation has 
not reached the bedside, stem-cell biology has granted great 
promise for tissue engineering and regenerative medicine. 
Treatments employing stem cells offer the potential to suc-
cessfully treat patients with new modalities in the future, by 
essentially regenerating and replacing non-functional tissues or 
organs. A permanent collaborative and multidisciplinary effort 
carried out by translational scientists with expertise in stem cells, 
bioengineering, and material science is undeniably necessary to 
fully develop alternative treatments for adrenal insufficiency that 
have true clinical relevance.
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